Real-world experience of anti-D immunoglobulin in immune thrombocytopenia
Tóm tắt
In developing countries, anti-D has been used in immune thrombocytopenia (ITP) as a cheaper alternative to human immunoglobulin. We aim to analyze the response and safety profile of anti-D in patients with severe ITP. A retrospective study was conducted at a tertiary care hospital in Northern India. Patients received a single intravenous infusion of 75 μg/kg anti-D. In total, 36 patients (20 females) were included in this study. The median duration from ITP diagnosis to anti-D therapy was 235 days (range 1–1613 days). Four (11.1%) patients received anti-D as an upfront treatment. The patients’ platelet counts rose significantly by the end of day three and continued to be significantly high until day 30 of receiving anti-D (p ≤ 0.001). The overall response rate (ORR) by day seven was 88.89%. There was no effect of age, sex, duration of disease, prior therapy, and platelet count on the ORR. Patients were followed up for a median duration of 52 days (longest follow-up: 3080 days). Six (6/36, 16.67%) patients continued to be in remission till the last follow-up. The hemoglobin fall was statistically significant on day three and day seven (p < 0.001 and p = 0.001) and got normalized by day 30. We observed equally good ORR in mixed populations and different phases of ITP along with long-term sustained response. The study demonstrates a quick and high response rate along with good safety profile to anti-D in all forms of ITP.
Tài liệu tham khảo
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386–2393
Tsuda H, Tsuji T, Tsuji M, Yamasaki H (2017) Life-threatening bleeding episodes in primary immune thrombocytopenia: a single-center retrospective study of 169 inpatients. Ann Hematol 96(11):1915–1920
Mishra K, Jandial A, Malhotra P, Varma N (2017) Wet purpura: a sinister sign in thrombocytopenia. BMJ Case Rep 2017:1–2
Nampoothiri RV, Singh C, Mishra K, Jandial A, Lad D, Prakash G et al (2017) Immune thrombocytopenia is the commonest diagnosis on consultative hematology—a single centre experience. Indian J Hematol Blood Transfus 33(Suppl 1):S104
Mishra K, Jandial A, Sandal R, Porchezhian P, Charan S, Kumar LDP et al (2018) Poor platelet function on sonoclot signature is associated with high incidence of bleeding in severe immune thrombocytopenia. Blood 132(Supplement 1):4991-
Mishra K, Kumar S, Jandial A, Sahu KK, Sandal R, Ahuja A et al (2021) Real-world experience of rituximab in immune thrombocytopenia. Indian Journal of Hematology and Blood Transfusion 37(3):404–413
Mishra K, Pramanik S, Sandal R, Jandial A, Sahu KK, Singh K et al (2021) Safety and efficacy of azathioprine in immune thrombocytopenia. Am J Blood Res 11(3):217–226
Mishra K, Pramanik S, Jandial A, Sahu KK, Sandal R, Ahuja A et al (2020) Real-world experience of eltrombopag in immune thrombocytopenia. Am J Blood Res 10(5):240–251
Mishra K, Sahu KK (2021) Re: Risk factors and predictors of treatment responses and complications in immune thrombocytopenia. Ann Hematol
Khera S, Pramanik SK, Yanamandra U, Mishra K, Kapoor R, Das S (2020) Dapsone: an old but effective therapy in pediatric refractory immune thrombocytopenia. Indian Journal of Hematology and Blood Transfusion:1–5
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N et al (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829–3866
Sandal R, Mishra K, Jandial A, Sahu KK, Siddiqui AD (2021) Update on diagnosis and treatment of immune thrombocytopenia. Expert Rev Clin Pharmacol 14(5):553–568
Salama A, Kiefel V, Amberg R, Mueller-Eckhardt C (1984) Treatment of autoimmune thrombocytopenic purpura with rhesus antibodies (anti-Rh0(D). Blut 49(1):29–35
Lazarus AH, Freedman J, Semple JW (1998) Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenic purpura (ITP): mechanisms of action. Transfus Sci 19(3):289–294
Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE et al (2001) Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98(4):1095–1099
Malinowska I, Obitko-Płudowska A, Buescher ES, Wasik M, Rokicka-Milewska R (2001) Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura. Hematol J 2(4):242–249
Sandler SG, Novak SC, Roland B (2000) The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin. Am J Hematol 63(3):156–158
Dhamija P, Bansal D, Srinivasan A, Bhalla A, Hota D, Chakrabarti A (2013) Patterns of prescription drug use and incidence of drug–drug interactions in patients reporting to medical emergency. Fundam Clin Pharmacol 27(2):231–237
Health NIo. Common Terminology Criteria for Adverse Events (CTCAE)Version 5.0 2017 [Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117(16):4190–4207
Team RDC (2008) R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing
Sahu KK, Siddiqui AD, Rezaei N, Cerny J. Challenges for management of immune thrombocytopenia during COVID-19 pandemic. J Med Virol. 2020.
Cooper N (2017) State of the art—how I manage immune thrombocytopenia. Br J Haematol 177(1):39–54
Ghanima W, Godeau B, Cines DB, Bussel JB (2012) How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood 120(5):960–969
El Alfy MS, Mokhtar GM, El-Laboudy MA, Khalifa AS (2006) Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. Acta Haematol 115(1–2):46–52
Newman GC, Novoa MV, Fodero EM, Lesser ML, Woloski BM, Bussel JB (2001) A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 112(4):1076–8
Tarantino MD, Young G, Bertolone SJ, Kalinyak KA, Shafer FE, Kulkarni R et al (2006) Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 148(4):489–494
Despotovic JM, Neunert CE (2013) Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia? Hematology 2013(1):283–285
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB et al (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115(2):168–186
Williams K (2016) Use of intravenous Anti-RhD immunoglobulin (RhIG) in the treatment of primary immune thrombocytopenia. American Society for Clinical Laboratory Science 29(2):92–97
Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM et al (1997) Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 89(8):2689–2700
Naithani R, Kumar R, Mahapatra M, Tyagi S, Saxena R (2009) Efficacy and safety of anti-D for treatment of adults with immune thrombocytopenia. Platelets 20(7):525–527
Rodeghiero F, Schiavotto C, Castaman G, Vespignani M, Ruggeri M, Dini E (1992) A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins. Haematologica 77(3):248–252
George JN, Raskob GE, Vesely SK, Moore D Jr, Lyons RM, Cobos E et al (2003) Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 74(3):161–169
Ramadan KM, El-Agnaf M (2005) Efficacy and response to intravenous anti-D immunoglobulin in chronic idiopathic thrombocytopenic purpura. Clin Lab Haematol 27(4):267–269
Papagianni A, Economou M, Tragiannidis A, Karatza E, Tsatra I, Gombakis N et al (2011) Standard-dose intravenous anti-D immunoglobulin versus intravenous immunoglobulin in the treatment of newly diagnosed childhood primary immune thrombocytopenia. J Pediatr Hematol Oncol 33(4):265–269
Shahgholi E, Vosough P, Sotoudeh K, Arjomandi K, Ansari S, Salehi S et al (2008) Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura. Indian J Pediatr 75(12):1231–1235
Krishnamurti L, Charan VD, Desai N, Pati H, Choudhry VP (1994) Anti-D immunoglobulin in the treatment of idiopathic thrombocytopenic purpura. Indian J Pediatr 61(2):179–182